• Q2 Brings First Same-Clinic Sales Growth in Five Quarters, Marks Strong Rebound in Unit Profitability
  • Leadership Advances Opportunities Across Key U.S. Markets
  • Positioned for Scalable, Sustainable Growth as Development Resumes with Renewed Focus

CHARLOTTE, N.C. – QC Kinetix, the largest regenerative medicine franchise in North America, officially relaunches its national franchise development initiative. The relaunch follows a year-long comprehensive brand transformation that strengthened operations, improved clinic performance, and significantly boosted unit-level profitability.

At a pivotal moment for both the brand and the broader regenerative medicine industry, which is projected to grow from $35.85 billion in 2024 to $169.55 billion globally by 2034, QC Kinetix is reactivating expansion in high-potential markets after a period of intentional evolution and system-wide optimization.

The relaunch comes on the heels of a major milestone: Q2 2025 marked the company’s first quarter of same-clinic sales growth in five quarters, an indicator of the success of QC Kinetix’s ‘QCK 2.0 transformation plan’, launched in July 2024. Over the same period, the brand has also completely reshaped its unit economics, increasing average clinic profitability 22.51 percentage points from 2.20% to +24.71%*, underscoring the effectiveness of its franchisee-focused strategy.

“Delivering the best possible outcomes for our patients and driving asset value for our franchise owners remain our top priorities,” said Mark Montini, CEO of QC Kinetix. “We made the intentional decision to pause development a year ago to strengthen our foundation, and the results have validated that choice. By instilling discipline and focusing on a few critical success drivers, we’ve built meaningful momentum for the brand. That combination makes this the right moment to begin growing again—six months earlier than we originally anticipated.”

The Transformation Delivered Results

The QCK 2.0 initiative, a three-phase transformation plan, was a complete reengineering of QC Kinetix’s business model, operating systems, and franchisee support infrastructure.

Key drivers of the transformation include:

  • A renewed cultural alignment bringing franchise owners, their teams, and corporate leadership together around both patient outcomes and business success.
  • Operating model enhancements designed to improve efficiency, clinical performance, and unit-level profitability.
  • Expanded support systems that equip franchisees with tools and resources to execute more effectively.
  • A sharpened focus on the brand’s original service lines—the foundation of its reputation and continued strength.
  • Strategic clinic consolidation to optimize market coverage and direct resources where they can deliver the most impact.

Development and Refranchising to Fuel Growth

Building on recent momentum, QC Kinetix will move forward with a two-part growth strategy:

  • New Franchise Development: Targeting 50 new franchise owners and 120 new clinics over the next 24 months through an updated development approach that prioritizes experienced operators who share the company’s vision and values.
  • Refranchising Opportunities: Transitioning select corporate-owned clinics to franchise ownership, creating opportunities for qualified operators while enabling the brand to focus more resources on supporting the success of every franchisee.

“Our franchise owners, their teams, and our corporate support staff have worked incredibly hard over the past year to completely transform our amazing brand and strengthen our foundation for growth,” added Montini. “Their efforts have put us in a strong position to begin welcoming new owners as we continue our leadership of the regenerative revolution.”

QC Kinetix franchise opportunities are available to both medical professionals and business-minded investors. Startup costs range from $250,100 to $655,080 for a single clinic, with multi-unit investments starting at $350,100**. QC Kinetix provides turnkey training, proven clinical protocols, and ongoing operational support to drive long-term success.

For more information about franchise opportunities with QC Kinetix, visit https://qckinetix.com/franchise/.

About QC Kinetix
Founded in 2017 and based in Charlotte, North Carolina, QC Kinetix is the largest regenerative medicine franchise in North America, recognized by the Inc. 5000 as one of America’s fastest-growing private companies. The brand delivers non-surgical, biologic-based treatments to help patients address joint pain, injuries, and musculoskeletal conditions by stimulating the body’s natural healing processes. QC Kinetix began franchising in 2020 and now operates more than 100 clinics across the U.S., with plans for 350 nationwide.

*This Marketing Communication is provided solely for general informational purposes. It does not constitute an offer to sell, or the solicitation of an offer to buy, a QC Kinetix® franchise. No franchise will be offered or sold to any prospective franchisee until the Franchisor has complied with all registration and disclosure requirements in the jurisdiction where the prospective franchisee resides or where the franchise will be located. Not an offer to sell a franchise in states where registration is required and not yet effective. Any statements in the Marketing Communication concerning prior clinic performance, future sales, profitability, growth projections, or similar matters (collectively, “Performance Statements”) are provided solely for illustrative purposes, reflect historical or forward-looking information as of the date of the Marketing Communication, and are inherently uncertain. Actual results will vary from clinic to clinic and may be materially affected by numerous factors within or outside a franchisee’s control, including the franchisee’s business acumen, local market conditions, staffing, competitive environment, and adherence to the System. No Performance Statement is intended or may be relied upon as a representation, warranty, or guaranty of any level of sales, costs, earnings, or success.

**Investment figures per the brand’s 2025 FDD.

Search